<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30385358</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2468-7189</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>29</Day>                    </PubDate>                </JournalIssue>                <Title>Gynecologie, obstetrique, fertilite &amp; senologie</Title>                <ISOAbbreviation>Gynecol Obstet Fertil Senol</ISOAbbreviation>            </Journal>            <ArticleTitle>[Contraception and cancer: CNGOF Contraception Guidelines].</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S2468-7189(18)30265-4</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.gofs.2018.10.010</ELocationID>            <Abstract>                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To synthesize knowledge on cancer risks related to hormonal contraception and to propose recommendations on contraception during treatment and after cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review of the literature about hormonal contraception and cancer was conducted on PubMed/Medline and the Cochrane Library.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, there is no increase in cancer (all types together) incidence or mortality among hormonal contraceptive users. Estroprogestin combined contraceptive use is associated with an increased risk of breast cancer (during use), and with a reduced risk of endometrial, ovarian, lymphatic or hematopoietic cancers that persist after discontinuation, and a decreased risk of colorectal cancer. Information on cancer risk is part of the systematic information given to patients wishing contraception. However, these data will not influence its prescription, considering the positive risk/benefit balance in women without specific cancer risk factor. Contraception is required during and after cancer treatment in every non-menopausal woman at cancer diagnosis. Specific thromboembolic, immunologic or vomiting risks due to the oncological context should be taken into account before the contraceptive choice. All hormonal contraceptives are contra-indicated after breast cancer, regardless of the delay since treatment, hormone receptor status and histological subtype. There is no data in the literature to limit hormonal or non-hormonal contraceptive use after colorectal or thyroid cancer. There was insufficient data in the literature to propose recommendations on contraceptive choice after cervical cancer, melanoma, lung cancer, tumor of the central nervous system, or after thoracic irradiation. If an emergency contraception is needed in a woman previously treated for a hormone-sensitive cancer, a non-hormonal copper intrauterine device should be preferred.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Information on cancer risk is part of the patient's information but does not influence the prescription of contraception in the absence of any specific risk factor. Contraception should be proposed in every woman treated or previously treated for cancer. The whole context should be taken into account to choose a tailored contraception.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Pragout</LastName>                    <ForeName>D</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Service de gynécologie obstétrique, unité d'orthogénie, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Laurence</LastName>                    <ForeName>V</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Département d'oncologie médicale, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Baffet</LastName>                    <ForeName>H</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Service de gynécologie médicale, orthogénie et médecine du couple, hôpital Jeanne-de-Flandre, CHRU de Lille, avenue Eugène-Avinée, 59037 Lille cedex, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Raccah-Tebeka</LastName>                    <ForeName>B</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Service de gynécologie-obstétrique, hôpital Robert-Debré, AP-HP, 75019 Paris, France.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rousset-Jablonski</LastName>                    <ForeName>C</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Département de chirurgie, centre de lutte contre le cancer Léon Bérard, 28, rue Laënnec, 69008 Lyon, France; Service de chirurgie gynécologique et oncologique - obstétrique, centre hospitalier Lyon Sud, 165, chemin du grand Revoyet, 69310 Pierre Bénite, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>fre</Language>            <PublicationTypeList>                <PublicationType UI="D004740">English Abstract</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <VernacularTitle>Contraception et cancer. RPC Contraception CNGOF.</VernacularTitle>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>29</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Gynecol Obstet Fertil Senol</MedlineTA>            <NlmUniqueID>101693805</NlmUniqueID>            <ISSNLinking>2468-7189</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Cancer du sein</Keyword>            <Keyword MajorTopicYN="N">Cancer recurrence</Keyword>            <Keyword MajorTopicYN="N">Cancer risk</Keyword>            <Keyword MajorTopicYN="N">Clinical guidelines</Keyword>            <Keyword MajorTopicYN="N">Contraception</Keyword>            <Keyword MajorTopicYN="N">Contraception after cancer</Keyword>            <Keyword MajorTopicYN="N">Contraception après cancer</Keyword>            <Keyword MajorTopicYN="N">Recommandations</Keyword>            <Keyword MajorTopicYN="N">Risque de cancer</Keyword>            <Keyword MajorTopicYN="N">Récidive de cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>10</Month>                <Day>03</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30385358</ArticleId>            <ArticleId IdType="pii">S2468-7189(18)30265-4</ArticleId>            <ArticleId IdType="doi">10.1016/j.gofs.2018.10.010</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>